ArticlePhysiological reports2026
COX2
Article in Physiological reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Liver fibrosis is a growing global health problem with no effective treatments. PDGFRα-positive fibroblasts are the main drivers of liver fibrosis, but their cellular heterogeneity is not fully understood. In this study, we performed single-cell RNA sequencing (scRNA-seq) on PDGFRα-positive fibroblasts isolated from healthy mouse livers. We also induced liver fibrosis via bile duct ligation (BDL) and examined their interactions with immune cells. scRNA-seq revealed that PDGFRα-positive fibroblasts mainly consist of hepatic stellate cells and portal fibroblasts. CellChat analysis indicated that a COX2-high (Ptgs2-high) subpopulation may preferentially interact with immune cells. This COX2-positive PDGFRα-positive fibroblast subset, also reported in other organs, localizes around bile ducts in the liver. Furthermore, when FACS-sorted PDGFRα-positive fibroblasts were treated with IL-1β in vitro, the proportion of COX2-positive cells increased. These findings demonstrate that PDGFRα-positive fibroblasts exhibit diversity in their responses to immune signals, with the COX2-positive subset potentially playing a key role in early fibrotic responses. Clarifying this heterogeneity may improve understanding of early liver fibrosis and support development of new therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.